Abstract
The combination of ombitasvir, dasabuvir, and paritaprevir/ritonavir (considered as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here, we describe an HIV-HCV-coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the atazanavir plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an atazanavir dose reduction guided by therapeutic drug monitoring.
MeSH terms
-
2-Naphthylamine
-
Anilides / administration & dosage
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / adverse effects
-
Atazanavir Sulfate / administration & dosage
-
Atazanavir Sulfate / adverse effects*
-
Atazanavir Sulfate / pharmacokinetics
-
Carbamates / administration & dosage
-
Coinfection
-
Cyclopropanes
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Drug Monitoring / methods
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / adverse effects
-
HIV Protease Inhibitors / pharmacokinetics
-
Hepatitis C / complications
-
Hepatitis C / drug therapy*
-
Humans
-
Hyperbilirubinemia / chemically induced*
-
Lactams, Macrocyclic
-
Macrocyclic Compounds / administration & dosage
-
Middle Aged
-
Proline / analogs & derivatives
-
Ritonavir / administration & dosage
-
Sulfonamides / administration & dosage
-
Uracil / administration & dosage
-
Uracil / analogs & derivatives
-
Valine
Substances
-
Anilides
-
Antiviral Agents
-
Carbamates
-
Cyclopropanes
-
HIV Protease Inhibitors
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
Sulfonamides
-
ombitasvir
-
Atazanavir Sulfate
-
Uracil
-
Proline
-
2-Naphthylamine
-
dasabuvir
-
Valine
-
Ritonavir
-
paritaprevir